Migraine Treatment Market By Treatment Type (Acute treatment and Prophylactic treatment), By Drug Class (Triptans, CGRP [Calcitonin Gene-Related Peptide] inhibitors, NSAIDs [Non-Steroidal Anti-Inflammatory Drugs], ergot alkaloids, beta-blockers, antidepressants, anticonvulsants, and others), By Route of Administration (oral, injectable, nasal sprays, and transdermal patches), By End User (Hospitals and clinics, home care settings, and specialty centers), Global Market Size, Segmental analysis, Regional Overview, Company share analysis, Leading Company Profiles, And Market Forecast, 2025 – 2035

Report Coverage:

By Treatment Type

• Acute Treatment
• Prophylactic Treatment

By Drug Class

• Triptans
• CGRP (Calcitonin Gene-Related Peptide) Inhibitors
• NSAIDs (Non-Steroidal Anti-Inflammatory Drugs)
• Ergot Alkaloids
• Beta-Blockers
• Antidepressants
• Anticonvulsants
• Others

By Route of Administration

• Oral
• Injectable
• Nasal Sprays
• Transdermal Patches

By End User

• Hospitals & Clinics
• Homecare Settings
• Specialty Centers

By Region

North America

• U.S.
• Canada

Europe

• U.K.
• France
• Germany
• Italy
• Spain
• Rest of Europe

Asia Pacific

• China
• Japan
• India
• Australia
• South Korea
• Singapore
• Rest of Asia Pacific

Latin America

• Brazil
• Argentina
• Mexico
• Rest of Latin America

Middle East & Africa

• GCC Countries
• South Africa
• Rest of the Middle East & Africa

List of Companies:

• Amgen Inc.
• Teva Pharmaceutical Industries Ltd.
• Eilly Lilly and Company
• Pfizer Inc.
• AbbVie Inc.
• Biohaven, LTD.
• Novartis AG
• AstraZeneca
• H. Lundbeck A/S
• Allergan
• Satsuma Pharmaceuticals, Inc.
• Zosano Pharma Corporation
• Ipsen Pharma
• Dr. Reddy’s Laboratories Ltd.
• Theranica Bio-Electronics Ltd.